US FDA approves Hycamtin for cervical cancer

	Tweet

Hycamtin, in combination with other chemotherapy agents, was approved by the U.S. Food and Drug Administration on Thursday to treat severe cases of cervical cancer in which surgery or radiation may not work.

Hycamtin (topotecan), sold by GlaxoSmithKline Plc, extended survival times by about three months when used with cisplatin, compared with treatment with cisplatin alone, the FDA said.

Because both drugs are already on the market and approved separately to treat other cancers, including ovarian and lung, doctors have already been able to use the combination for cervical cancer. The FDA’s ruling give the agency’s stamp-of-approval and allows Glaxo to market the drug for the expanded use.

The combination should be used after ruling out other options when the disease is incurable, recurrent or has spread to other organs, the agency said.

Last week the FDA approved Merck and Co. Inc.’s vaccine for human papillomavirus, the leading cause of cervical cancer. Glaxo is developing its own HPV vaccine and expects to seek U.S. approval later this year.

About 10,000 American women are diagnosed with the disease each year and another 3,700 die, according to the FDA.

The agency said it based its decision on clinical data of 293 patients that showed those taking Hycamtin and cisplatin lived an average of 9.4 months, while those taking cisplatin alone lived 6.5 months.

“This course of drug therapy is a potentially life-prolonging option for thousands of women,” FDA Acting Commissioner Andrew von Eschenbach said in a statement.

Hycamtin, which is given by infusion, can damage the immune system by lowering white blood cell counts crucial to fighting infection; decreasing blood platelets that prevent bleeding; and depleting red blood cells that can cause anemia. Nausea, vomiting, diarrhea and hair loss are also side effects.

Hycamtin is part of a class of anti-cancer drugs known as topoisomerase I inhibitors that interrupt the replication of DNA in cancer cells, causing them to die.

RELATED STORIES:
Cervical cancer drops, but disparities persist   Aspirin Merits Testing for Prevention of Cervical Cancer in HIV-Infected Women   Scientists identify how virus triggers cervical and mouth cancer   Merck’s cervical cancer vaccine on sale in Europe   Doctors say HPV vaccine should be given to everyone   Smoking raises virus-related cervical cancer risk   Higher rates of cervical cancer amongst immigrants   Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia   High HPV Concentrations, Smoking Significantly Raise Risks of Cancer   Coils almost halve risk of cervical cancer: study   Fewer than 3 doses of cervical cancer vaccine effective   Gates cash backs cervical cancer shots for poor   Women with AIDS face cervical cancer threat   How Medical Center Research Led to New Cervical Cancer Vaccine   Women diagnosed with precancerous CIN at risk for cervical cancer   Cervical cancer vaccine tipped for nine year olds   Cervical cancer vaccines in development   Cervical Cancer Rates Higher Among Minority Women   “Screen and treat” cervical cancer programs effective in poorly resourced areas   Vaccine no replacement for Pap test   Merck cervical cancer shot gives 5-year protection   CDC recommends human papillomavirus virus vaccination

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]